Entries by Gina Wentling

Development of an In Vitro Assay to Predict Cardiotoxicity Potential Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [SOT 2018]

Presented at the Society of Toxicology Annual Meeting and ToxEXPO in San Antonio, Texas, March 2018, by Stemina’s Associate Director of Toxicology, Jessica Palmer.

Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of the safety-related withdrawals of FDA-approved drugs from the market. Metabolic perturbations are one of the primary mechanisms of cardiotoxicity elicited by pharmaceuticals…

Application of a Human Pluripotent Stem Cell-Based Assay for Developmental Toxicity Screening [Tox Forum 2018 – Presentation Slides]

Presented at The Toxicology Forum’s 42nd Annual Winter Meeting in Washington, DC in January 2018 by Stemina’s Associate Director of Toxicology, Jessica Palmer.

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) recently released the draft S5(R3) Guideline on Detection of Toxicity to Reproduction for Human Pharmaceuticals…

Development of a Targeted Biomarker Assay to Predict Cardiotoxicity Potential Using Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [ACT 2017]

Presented at the American College of Toxicology’s 38th Annual Meeting in Palm Springs, California in November 2017 by Stemina’s Associate Director of Toxicology, Jessica Palmer.

Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of the safety related withdrawals of FDA-approved drugs from the market…

Developmental Toxicity Potency of Valproate Analogues in a Human Pluripotent Stem Cell-Based Assay -[Northland Chapter of SOT, 2017 – Slides]

Presented at the Annual Meeting of the Northland Chapter of the Society of Toxicology (September 2017) by Jessica Palmer, Associate Director of Toxicology.

Development and validation of alternative models for developmental toxicity testing is essential for reducing the number of animals used for toxicity testing. While replacing animal models has been at the forefront of the toxicology field for over a decade…